Tenax Therapeutics, Inc. (TENX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Tenax Therapeutics, Inc. (TENX) closed at USD 1.51 on 2026-10-15, a change of -79.1 % over the past year, with a market capitalization of USD 50.9M.

Tenax Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Tenax Therapeutics, Inc. key figures

Previous close

USD 1.51 (2026-10-15)

1-year change

-79.1 %

Market cap

USD 50.9M

Enterprise value

USD -40.07M

P/E ratio (trailing)

-0.92

P/E ratio (forward)

-0.91

EPS (trailing)

-1.48

EPS (forward)

-1.50

PEG ratio

1.44

Price to book

0.62

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.49

Employees

14

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Tenax Therapeutics, Inc. and compare it with other stocks.